Combination of target agents: challenges and opportunities.
Ardizzoni
Andrea
A
Department of Oncology, Azienda Ospedaliero, Universitaria di Parma, Parma, Italy. aardizzoni@ao.pr.it
Tiseo
Marcello
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology; D008175:Lung Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology; D011758:Pyrroles / Q000008:administration & dosage / Q000494:pharmacology; D011799:Quinazolines / Q000008:administration & dosage / Q000494:pharmacology; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D000077157:Sorafenib; D000077210:Sunitinib
D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D010880:Piperidines; D011725:Pyridines; D011758:Pyrroles; D011799:Quinazolines; D009536:Niacinamide; D000077157:Sorafenib; D020794:Receptor Protein-Tyrosine Kinases; D000077210:Sunitinib; C452423:vandetanib